Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARLISSA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and are using oral contraception,Treatment of premenstrual dysphoric disorder (PMDD)
Prevention of pregnancy
MARLISSA 20 mg orally once daily with or without food.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Drospirenone is metabolized by CYP3A4 to inactive metabolites.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
95-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.6-0.8 L/kg (approximately 42-56 L in a 70 kg adult). High Vd indicates extensive tissue distribution, including into the central nervous system and, in pregnancy, across the placenta.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 80-90% (range 75-95%) with minimal first-pass metabolism. Rectal: 70-80% of oral bioavailability. Intravenous: 100%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
e GFR ≥30 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 10 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg once daily; Child-Pugh C: not recommended.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Starting dose 10 mg once daily in patients ≥75 years; titrate based on tolerance and renal function.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), especially in women with hypertension, hyperlipidemia, obesity, or diabetes. Hepatic neoplasia, gallbladder disease, hypertension, headache, carbohydrate and lipid metabolism effects, and depression. Discontinue if jaundice, visual disturbances, or migraine occurs.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
History of or current venous thromboembolic disease, arterial thromboembolic disease, cerebrovascular disease, coronary artery disease, thrombogenic valvular or rhythm disorders (e.g., atrial fibrillation), inherited or acquired hypercoagulopathies, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, known or suspected pregnancy, liver disease or hepatic adenoma/carcinoma, malignancy (breast, endometrial, or other estrogen-sensitive), undiagnosed abnormal uterine bleeding, hypersensitivity to any component, renal insufficiency (creatinine clearance <50 m L/min), adrenal insufficiency, and smoking in women over 35.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No clinically significant food interactions reported. Administer without regard to meals.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: Malformations (neural tube defects, cardiac anomalies) increased 2-3 fold. Second/third trimester: Fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated. M/P ratio unknown. Excreted in breast milk; potential for infant toxicity.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Increase dose by 30-50% in second and third trimesters due to increased clearance; monitor therapeutic levels.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
MARLISSA (belimumab) is a monoclonal antibody indicated for systemic lupus erythematosus. Monitor for hypersensitivity reactions during infusion. Do not administer concurrently with live vaccines. Assess for depression and suicidal ideation before and during treatment. Consider baseline Ig G levels as hypogammaglobulinemia may occur.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately during infusion.,Avoid live vaccines while on MARLISSA; discuss vaccination schedule with your doctor.,Notify your doctor if you experience new or worsening depression, mood changes, or suicidal thoughts.,Inform your doctor if you have a history of infections, as MARLISSA may increase infection risk.,Do not breastfeed while using MARLISSA unless advised by your healthcare provider.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARLISSA vs ALYACEN 7/7/7, answered by our medical review team.
MARLISSA is a Oral Contraceptive that works by MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARLISSA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARLISSA is: MARLISSA 20 mg orally once daily with or without food.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARLISSA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARLISSA is classified as Category C. First trimester: Malformations (neural tube defects, cardiac anomalies) increased 2-3 fold. Second/third trimester: Fetal growth restriction, oligohydramnios, premature closure of . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.